Led · Equity · Oct 2025

Intellego Technologies is a Swedish firm that designs and sells products within UV-dosimetry and water-purification, aiming to improve disinfection and sanitation processes. The company is positioning its technology for global healthcare and industrial markets and is currently collaborating with a large Chinese disinfection partner that services roughly 8,000 hospitals. Management plans to accelerate both organic growth and strategic acquisitions, with a particular focus on expanding in Asia. Despite recent market turbulence, Intellego states it still holds more than SEK 100 million in cash and available credit lines. The fresh capital injection is expected to bolster its balance sheet, restore market confidence, and provide resources to scale production and distribution. Future growth initiatives include broadening the UV-dosimeter portfolio and entering additional application areas in water treatment.

Participated · Series C · Mar 2022

Modulus Discovery is a preclinical-stage, computation-driven drug discovery company with offices in Tokyo and Boston that applies a proprietary simulation-driven platform to small-molecule discovery. The company runs a globally networked, fabless operational model and manages a discovery portfolio of more than 10 R&D programs. Since launching its discovery portfolio in 2018, Modulus reports positive in vivo proof-of-concept results for three of its most advanced lead programs. Its near-term plan is to advance those candidates toward first-in-human clinical trials in collaboration with partners. Modulus intends to use new capital to expand platform infrastructure, deepen industry and academic collaborations, and grow R&D and operations headcount. The firm focuses on therapeutic areas including oncology, chronic inflammation/immune disorders, and rare genetic conditions. Financially, Modulus has raised capital to date and is positioning to deliver multiple clinical candidates through partnerships and additional discovery collaborations. Modulus Discovery is a preclinical-stage, technology-driven drug discovery firm operating a computational discovery platform and networked operations with offices in Tokyo and Boston. The company focuses on discovering and optimizing small-molecule lead programs in oncology, chronic inflammation/immune disorders, and rare genetic conditions using supercomputing and computational biology. Modulus operates a virtual‑pharma model that does not own experimental lab space and instead leverages simulation and partnerships to advance candidates. The firm says it has identified and characterized several unique lead molecules and intends to bring them closer to clinical testing through partnerships with major industry players. Modulus plans to expand its portfolio of early programs and collaborations, including work with strategic partner PeptiDream, Inc. Financially, the company has raised a total of ¥3.51B (approximately $33.1M USD) to date across its Series A and B rounds. Modulus Discovery is a private, Tokyo-based preclinical drug discovery company that uses a proprietary computational platform and biology insights to design and generate small-molecule clinical candidates. The company operates a virtual pharma model and maintains an international team of drug design and disease biology experts with prior R&D experience at global pharma, biotech, and computational firms. Modulus plans to use new capital to further develop its platform, accelerate collaborative drug discovery programs with PeptiDream, and expand its R&D and business teams. Management also intends to initiate additional global collaborations with industry and academic partners that show strong synergy with Modulus’ capabilities. The company has offices and global virtual operations including Tokyo and Boston and reported progress from its collaboration with PeptiDream that produced several promising hit peptides. Financially, Modulus completed a Series A raise of ¥800M (approximately US$7.2M) to support these initiatives.

Participated · Series B · Feb 2021

Cullgen is a privately held clinical-stage biopharmaceutical company applying its proprietary uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination) platform to develop first-in-class new chemical entities. The company focuses on targeted protein degradation to expand drug design beyond functional site inhibition and to target historically “undruggable” proteins. Cullgen has generated multiple highly potent, selective, and bioavailable targeted protein degrader compounds that utilize proprietary novel E3 ligands. Its internal pipeline targets oncology and other diseases. The company said the new financing will support development of its technology platform and internal pipeline of targeted protein degraders. Cullgen is identified with offices/operations in San Diego and Shanghai in the announcement. Cullgen develops small-molecule therapeutics using its proprietary uSMITE™ ubiquitin-mediated targeted protein degradation platform. The company is advancing an internal pipeline of targeted protein degraders for oncology and other diseases and emphasizes discovery of novel E3 ligands. Cullgen plans to file an IND later this year for its most advanced program, CG001419, a TRK protein degrader, and intends to use new capital to move programs into human clinical studies. The company says its uSMITE™ approach enables elimination of previously “undruggable” proteins and aims to be more cost effective than traditional drug discovery. Cullgen operates out of San Diego and Shanghai and is privately held. Cullgen develops targeted protein degraders using its proprietary uSMITE™ (ubiquitin mediated small molecule induced target elimination) platform. The company focuses research programs on novel treatments for cancer, inflammatory, and autoimmune diseases. Cullgen has identified several pre-clinical assets that it is advancing toward the clinic. It is also working to discover novel E3 ligands to incorporate into degrader complexes. Over the past year the company assembled a board of scientific advisors, established a senior management team, and built a state-of-the-art laboratory facility. The lab is run by more than 40 employees. The company intends to use its platform and assets to progress programs into clinical development. Cullgen is building a drug discovery platform based on advanced ubiquitin-mediated protein degradation technology that enables selective degradation of disease-causing proteins, including targets previously considered undruggable. The platform draws on Dr. Yue Xiong’s foundational work since 1998 identifying catalytic and regulatory components and assembly mechanisms of cullin-RING E3 ubiquitin ligases. Cullgen’s founders, including Dr. Xiong and Dr. Jian Jin, have developed multiple new chemical entities (NCEs) against cancer targets and have filed multiple patent applications. Initial discovery programs will focus on oncology with planned expansion into inflammatory and autoimmune diseases. The company is incorporated in Delaware and will initiate research operations in the United States, Japan, and China. Cullgen has established a scientific advisory board and a board of directors that includes executives from its lead investor, GNIG.

Participated · Equity · Nov 2020

MedAvail provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and operates home delivery services for Medicare clinics. Its core product is an automated in-clinic pharmacy platform designed to improve medication adherence and clinical outcomes. The company completed a private placement that raised approximately $84 million in gross proceeds prior to the closing of its announced business combination. That financing resulted in the issuance of roughly 12.3 million shares of MedAvail common stock. Proceeds are earmarked to support strategic growth initiatives and general corporate purposes, including expanding its footprint in the United States and building instant and remote pharmacy services. Cowen and Company served as lead placement agent, with Lake Street Capital Markets acting as a placement agent. MedAvail operates the MedAvail MedCenter™, a kiosk-based, mobile-enabled self-service pharmacy platform that enables automated medication dispenses under the supervision of licensed tele-pharmacists in under 90 seconds. The MedCenter provides 24/7, multi-lingual pharmacist access via built-in audio-visual communications and licensed tele-pharmacists perform all professional functions associated with prescription dispensing. MedAvail has deployed its platform in the U.S. and internationally with customers that include Walgreens, Banner Health, Geisinger, and Bayless Integrated Health. Company data shows MedCenters in physician clinics fill 25–40% of prescriptions written by the clinic and about 35% in hospital sites; MedAvail says on‑premise MedCenters increase medication adherence to 100% versus approximately 70% pickup rates. The company positions its turnkey offering as a low cost-to-fill "last mile" channel for pharmacy retailers, hospital systems, clinic operators, employers and new market entrants. This round of financing will help scale MedAvail’s commercial activities in the U.S. and overseas. MedAvail Technologies is a Toronto, Canada-based healthcare solution company that commercializes the MedAvail MedCenter prescription-drug dispensing kiosk. The MedCenter is a consumer-facing kiosk providing live two-way audio-visual interaction with a remote pharmacist. The solution is intended for deployment in hospitals, clinics, retail locations, pharmacies and employer sites. Deployments of the MedCenter are currently ramping up in the US, Canada and Europe. MedAvail intends to use the proceeds from the financing to fund commercialization of the MedCenter. The company is led by CEO Ed Kilroy and recently added Dr. Frank Litvack of Pura Vida Investments to its board.